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Background
The somatically related antibodies, PG9 and PG16, neutra-
lize 70-80% of HIV-1 isolates and bind a glycosylated epi-
tope in the V1/V2 domain of HIV-1 gp120. Mutations in
V1/V2, and sometimes V3 depending on the HIV-1 strain,
affect neutralization and a glycan on Asn160 is required
for neutralization. Both antibodies also preferentially bind
the native trimer over monomeric gp120, especially PG16.
The structure of PG9 in complex with its epitope, a scaf-
folded V1/V2 from HIV-1 strain ZM109, was recently
solved and showed that PG9 targets a site of vulnerability
comprising 2 glycans and a b-strand.
Methods
To understand the differences in binding properties from
these two somatically related antibodies, we first assessed
their binding to monomeric gp120 and scaffolded V1/V2
proteins with different glycan types (oligomannose, hybrid,
and complex). In order for PG16 to bind the scaffolded
V1/V2, the protein had to be expressed in mammalian
cells in the presence of swainsonine, which inhibits glycan
maturation past the hybrid state. A stable complex could
be obtained between PG16 and a scaffolded V1/V2
domain from ZM109, and this complex was crystallized.
Results
Although the structure of PG16 bound to scaffolded V1/
V2 resembled that of PG9, some differences were seen: 1)
PG16 binding to the b-strand is weaker than PG9 with
fewer charged interactions, 2) PG16 interacts with a hybrid
glycan at position N173. The difference in binding recog-
nition of PG9 and PG16 to monomeric gp120 depends on
the type of glycans present. PG16 binds the protein por-
tion of V1/V2 weaker than PG9 and this might explain the
higher affinity of PG9 for the monomer. PG16 has evolved
a second glycan site to compensate for weaker peptide
interaction.
Conclusion
The results show the importance of polyclonal response
in infected individual to combat HIV-1, and in this case,
to differential glycosylation.
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